Clinical Trial Update: A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of CM336 in relapsed or refractory multiple myeloma is ongoing and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CM336 (CM336)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING